tkmr改新名称，新网站

newchinabok

http://www.tekmira.com/

newchinabok

http://www.bizjournals.com/phila ... dicine.html?s=print

newchinabok

Bucks County researchers in hunt for hepatitis B cure
Jul 31, 2015, 12:37pm EDT
Mike Sofia
John George
Arbutus BioPharma Chief Scientific Officer Michael J. Sofia at the Pennsylvania Biotechnology Center in Doylestown, Pa.

John George
Senior Reporter- Philadelphia Business Journal
Email  |  Twitter  |  Google+
A Canadian drug company with research facilities in Bucks County expects to begin human testing of four potential hepatitis B treatments during the first half of next year.
Doylestown-based researcher Michael J. Sofia — inventor of Gilead Siences Inc.’s multibillion-dollar drug Sovaldi, used to cure hepatitis C — is the chief scientific officer of OnCore BioPharma that is set to rebrand itself as Arbutus BioPharma Corp. (NASDAQ: ABUS) starting Monday.
Wistar CEO: Congress should support more government funded research
Company officials said the name change “affirms the successful integration” of OnCore BioPharma — which is based at the Pennsylvania Biotechnology Center of Bucks County — and Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) of Vancouver, British Columbia.
OnCore had filed plans late last year to go public before deciding in January to pursue a merger with publicly traded Tekmira.
The single goal of Arbutus BioPharma will be to deliver a cure for chronic hepatitis B, a liver infection that afflicts 2 billion people worldwide including 12 million in the United States.
Woman-founded startups more successful: Study
Tekmira CEO Dr. Mark J. Murray, will serve as president and CEO of Arbutus. OnCore co-founder Patrick T. Higgins, who worked with Sofia at Princeton-based Pharmasset where Sovaldi was developed, is chief business officer at Arbutus. Another Pharmasset colleague, William T. Symonds, is the company’s chief development officer.
“We are very excited about the prospects for our integrated new company,” Murray said.
Murray said the company believes the market opportunity for a treatment to cure the hepatitis B virus infection is “very significant, likely eclipsing” the market for drugs being used to cure hepatitis C.
Obama nominates Philly judge to federal bench
Solvaldi generated sales of $10.3 billion in 2014 for Gilead, which paid $11.5 billion to acquire Pharmasset in 2011. With competition from other hepatitis C drugs led by AbbVie’s Viekira-Pak, Sovaldi sales are not on the same pace this year. During the fist six months of 2015, Sovaldi sales totaled $2.3 billion.
In seeking a cure for hepatitis B, Arbutus plans to use a strategy patterned after the game plan of Pharmasset team led by Sofia that resulted in Sovaldi. That strategy will involve first establishing safety and activity of individual product candidates, then conducting small studies of therapies combining the lead product candidates to identify the most promising regimens. That will be followed by larger studies testing various combinations, doses and treatment durations.
The company is committed to having at least four hepatitis B virus treatment candidates advance into clinical development during the first half of 2016. It also expects to file applications to begin testing for three additional experimental hepatitis B virus therapies next year.

newchinabok

雄鹿县研究人员在寻找乙肝治疗

杨梅生物制药的首席科学官Michael J.索菲亚在宾夕法尼亚州的生物技术中心的Doylestown，宾夕法尼亚州。


一个加拿大制药公司与研究机构巴克斯县预计在明年上半年开始的四个潜在乙肝治疗人体试验。
多伊尔斯敦的研究员迈克尔·索菲亚 - 基列的公司Siences的数十亿美元的毒品Sovaldi，用于治疗丙型肝炎的发明者 - 是OnCore生物制药被设置为自己更名为杨梅生物制药公司的首席科学官（纳斯达克股票代码：安博）周一开始。
CEO的Wistar：国会应该支持更多的政府资助的研究
公司官员说，更名“确认成功整合”OnCore生物制药 - 这是设在巴克斯县的宾夕法尼亚生物技术中心 - 和Tekmira制药公司：温哥华（NASDAQ TKMR），不列颠哥伦比亚省。
OnCore已经向计划去年年底决定在一月份继续与上市Tekmira合并前上市。
杨梅生物制药的唯一目标是提供一种治疗慢性乙型肝炎，肝感染的折磨2十亿全世界人民，包括美国1200万美元。
女人创立的创业公司更成功：研究
Tekmira CEO马克博士J.穆雷，将作为杨梅的总裁兼首席执行官。 OnCore联合创始人帕特里克·希金斯吨，谁在那里Sovaldi开发普林斯顿为主Pharmasset曾与索非亚，是首席商务官杨梅。另一位同事Pharmasset，威廉·T·西蒙兹，是该公司的首席开发官。
“我们非常高兴为我们的集成新公司的前景，”穆雷说。
穆雷表示，该公司认为，为一个治疗市场机会治愈乙肝病毒感染是“非常显著，可能高一筹”市场对药品被用于治疗丙型肝炎。
奥巴马提名法官费城联邦替补
Solvaldi产生在2014年销量达103十亿为吉利德，其中支付了$ 11.5十亿收购Pharmasset在2011年从为首的艾伯维的Viekira朴其他丙型肝炎药物竞争，Sovaldi销售不在同一步调今年。在2015年的拳头半年，Sovaldi销售总额为2.3十亿。
在寻求治愈乙肝，杨梅计划用Pharmasset带领的团队索非亚，导致Sovaldi的比赛计划后图案的战略。这一战略将涉及个人的候选产品首先确定安全性和活动，然后进行治疗相结合的主导产品候选人，以确定最有前途的治疗方案的小型研究。这之后，将较大的研究试验各种组合，剂量和治疗时间。
公司致力于以具有至少四个乙肝病毒治疗的候选人提前进入临床开发过程中的第一个2016年上半年该公司还预计提交申请，开始对另外三个实验乙肝病毒的治疗试验明年。

newchinabok

NASDAQ: ABUS

newchinabok

http://www.bizjournals.com/phila ... ichael-j-sofia.html

newchinabok

Tekmira Announces Launch of Arbutus Biopharma, a Hepatitis B Solutions Company
Tekmira Pharmaceuticals


Four HBV Product Candidates Advancing In Human Clinical Trials in 1H16

Three IND Filings in 2016 for Oral HBV Drug Candidates Targeting cccDNA, S-Antigen, and Core Protein

New Business Unit Established to Maximize Value of Tekmira's Non-HBV Assets

VANCOUVER, British Columbia and DOYLESTOWN, Pa., July 20, 2015 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TKMR) today announced plans to change its corporate name to Arbutus Biopharma Corporation ("Arbutus", ticker symbol "ABUS"), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before August 3, 2015. The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the singular goal of delivering a cure for chronic HBV. The combined entity currently fields the largest portfolio of HBV product candidates in the industry and is led by an experienced and proven leadership team shown below with notable prior experience.

Mark J. Murray, Ph.D., President and CEO; formerly of Protiva, Zymogentics, and Xcyte Therapeutics
Patrick T. Higgins, Chief Business Officer; co-founder of OnCore BioPharma; formerly of Pharmasset and Roche
Bruce Cousins, Chief Financial Officer; formerly of Aspreva and Johnson & Johnson
Michael J. Sofia, Ph.D., Chief Scientific Officer; co-founder of OnCore BioPharma; formerly of Pharmasset (inventor of sofosbuvir for hepatitis C), Bristol-Myers Squibb, and Eli Lilly
William T. Symonds, Pharm.D., Chief Development Officer; formerly of Gilead Sciences, Pharmasset (clinical development of sofosbuvir for hepatitis C), and GlaxoSmithKline
Mark Kowalski, MD, Chief Medical Officer; formerly of Gilead Sciences, YM BioSciences, and Viventia Biotechnologies
Peter Lutwyche Ph.D., Chief Technology Officer, formerly of Protiva, QLT, and Inex Pharmaceuticals
"We are very excited about the prospects for our integrated new company, which has undergone a transformation to a complete HBV solutions company. The company possesses exceptionally strong and proven clinical development, scientific, and commercial leadership teams and is very well resourced to execute against our goal of delivering a cure for chronic HBV. We believe that the market opportunity for a curative regimen for HBV is very significant, likely eclipsing the HCV market, and presents a meaningful opportunity for shareholders," said Dr. Mark J. Murray, President and CEO of Tekmira. "We remain very confident in our potential to create value from our industry-leading strategy, team, and pipeline dedicated to developing therapeutic solutions to cure HBV."

newchinabok

杨梅生物制药，乙型肝炎解决方案的公司Tekmira宣布推出
Tekmira制药


四HBV候选产品推进人体临床试验在1H16

在2016年三IND申请量为口服药物乙肝病毒靶向考生cccDNA的，S-抗原和核心蛋白

新的业务部门成立最大化Tekmira非HBV资产价值

温哥华，不列颠哥伦比亚省和DOYLESTOWN，霸，二零一五年七月二十〇日（GLOBE NEWSWIRE） - Tekmira制药公司（TKMR）今天宣布，计划更改其企业名称杨梅生物制药股份有限公司（“杨梅”，股票代码为“安博”），业界领先的治疗解决方案公司，专注于开发治疗慢性乙型肝炎病毒感染（HBV），是有效的8月3日或之前，2015年更名肯定OnCore生物制药和医药Tekmira的成功整合成一个合并后的公司与提供一个治疗慢性乙型肝炎的唯一宗旨。合并后的公司目前场的HBV候选产品中最大的投资组合中的行业及公司由具有显着以往的经验显示如下的经验和出色的领导团队。

马克J.默里，博士，总裁兼首席执行官;以前的Protiva的，Zymogentics和Xcyte治疗
帕特里克·希金斯吨，首席商务官; OnCore生物制药的创始人之一;原Pharmasset和罗氏
布鲁斯·考辛斯，财务总监;以前的Aspreva和强生公司
迈克尔·索菲亚，博士，首席科学官; OnCore生物制药的创始人之一;原Pharmasset（发明者索非布韦的丙型肝炎），百时美施贵宝和礼来的
威廉·T·西蒙兹，药学博士，首席开发官。以前的吉利德科学，Pharmasset（索非布韦的丙肝临床开发）和葛兰素史克
马克·科瓦尔斯基，医学博士，首席医疗官;以前的吉利德科学，生物科学YM和Viventia生物技术
彼得Lutwyche博士，首席技术执行官，原Protiva的，QLT，而INEX制药
“我们非常高兴为我们的集成新的公司，它已经发生了转变为一个完整的解决方案，乙肝公司的前景。公司拥有异常强大和成熟的临床开发，科学和商业领导团队并很好的资源，以执行对我们提供一个治疗慢性乙型肝炎的目标。我们相信，一个疗程治愈乙肝的市场机会非常显著，可能遮盖了HCV市场，并提出股东有意义的机会，“马克博士J.默里，总统说，和Tekmira的首席执行官。 “我们仍然非常有信心在我们的潜能，创造从我们业界领先的战略，团队的价值，以及管道致力于开发治​​疗方案治愈乙肝。”

newchinabok

http://media.globenewswire.com/cache/14025/file/35721.pdf

jaylongli

现在是临床几期？遥遥无期的感觉